Licensing Opportunities

Opportunity TitleDescriptionRead More
Biomarker panel for Triple Negative Breast Cancer

Novel panels of epigenetic biomarkers for (1) diagnosis of triple negative breast cancer and detection of minimal residual disease; and (2) predicting prognosis of patients with triple negative breast cancer.

Read more  View or download the flyer
Anticancer antibody targeting NPY & PYY A humanised monoclonal antibody functioning via a novel mechanism of action that effectively neutralizes NPY/PYY, reducing tumour growth and increasing survival in animal tumour models. The antibody has a dual effect; directly targeting the tumour in addition to modulation of the immune system.  Read more – View or download the flyer
New target for insulin resistance & Type-2 Diabetes: PKCε The lipid-regulated protein kinase C isoform, PKCε, plays a central role in β-cell dysfunction. Inhibition of PKCε corrects multiple dysfunctions associated with type-2 diabetes - including increasing glucose stimulated insulin secretion - with minimal side effects, providing unique benefits over existing therapies.  Read more – View or download the flyer
Novel marker for diagnosis of ovarian cancer A novel diagnostic biomarker for the detection of ovarian cancer.  Hyper-methylation of LOC134466 - indicative of the presence of cancer and measurable in blood measured – is candidate marker for early detection and post-surgical surveillance or monitoring the success of treatment and relapse/recurrence of disease. Read more – View or download the flyer

© Garvan Institute 2017